Patents by Inventor Liu Xue

Liu Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240076375
    Abstract: Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.
    Type: Application
    Filed: September 27, 2023
    Publication date: March 7, 2024
    Inventors: Tong Zhang, Liu Xue, Qi Liu, Hao Peng, Min Wei, Kang Li
  • Publication number: 20230391883
    Abstract: Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and antigen-binding fragments thereof in combination with an anti-PD1 antibody.
    Type: Application
    Filed: January 20, 2022
    Publication date: December 7, 2023
    Inventors: Tong Zhang, Liu Xue, Qi Liu, Min Wei, Kang Li, Yunxia Zuo
  • Publication number: 20220251195
    Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 11, 2022
    Inventors: Tong ZHANG, Liu XUE, Qi LIU, Min WEI, Kang LI
  • Publication number: 20220153837
    Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 19, 2022
    Inventors: Tong ZHANG, Liu XUE, Qi LIU, Min WEI, Kang LI
  • Publication number: 20220135675
    Abstract: Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.
    Type: Application
    Filed: November 15, 2021
    Publication date: May 5, 2022
    Inventors: Tong ZHANG, Liu XUE, Qi LIU, Hao PENG, Min WEI, Kang LI
  • Patent number: 11214616
    Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.
    Type: Grant
    Filed: December 29, 2018
    Date of Patent: January 4, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Tong Zhang, Liu Xue, Qi Liu, Min Wei, Kang Li
  • Patent number: 11203637
    Abstract: Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 21, 2021
    Assignee: BEIGENE, LTD.
    Inventors: Tong Zhang, Liu Xue, Qi Liu, Hao Peng, Min Wei, Kang Li
  • Publication number: 20200331999
    Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.
    Type: Application
    Filed: December 29, 2018
    Publication date: October 22, 2020
    Inventors: Tong ZHANG, Liu XUE, Qi LIU, Min WEI, Kang LI
  • Patent number: 10772940
    Abstract: The presently-disclosed subject matter includes isolated polypeptides that comprise a butyrylcholinestrase (BChE) polypeptide and a second polypeptide. The BChE polypeptide as well as the second polypeptide can be variants and/or fragments thereof. The presently-disclosed subject matter also includes a pharmaceutical composition that comprises the present isolated polypeptide and a suitable pharmaceutical carrier. Further still, methods are provided for treating cocaine-induced conditions, and comprise administering the isolated polypeptide and/or pharmaceutical compositions thereof to an individual.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: September 15, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Hsin-Hsiung Tai, Xiabin Chen, Liu Xue, Shurong Hou
  • Publication number: 20190276533
    Abstract: Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.
    Type: Application
    Filed: August 25, 2017
    Publication date: September 12, 2019
    Inventors: Tong Zhang, Liu Xue, Qi Liu, Hao Peng, Min Wei, Kang Li
  • Patent number: 9365841
    Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 14, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Wenchao Yang, Liu Xue, Shurong Hou
  • Patent number: 8945901
    Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: February 3, 2015
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Wenchao Yang, Liu Xue, Shurong Hou
  • Patent number: 8592193
    Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: November 26, 2013
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Wenchao Yang, Liu Xue, Shurong Hou
  • Publication number: 20080156235
    Abstract: Apparatus and system for leveling a playing surface on a table, such as a billiards or pool table, which utilizes a plate which supports the playing surface and which is tiltable about an x and y-axis for maintaining contact with the playing surface regardless the angle of the surface relative to the frame. Further, the apparatus is height adjustable to assist with leveling the playing surface in engagement with the plate of the leveling apparatus. Leveling apparatus are also provided between the legs of the table and the frame and which can be pre-leveled before positioning the playing surface to minimize the amount of leveling required to level the playing surface relative to the frame.
    Type: Application
    Filed: December 27, 2006
    Publication date: July 3, 2008
    Applicant: ZHONGSHAN RISING DRAGON BILLIARD CO. LTD.
    Inventors: John Paul KEIRSTEAD, Darcy AMENDT, Glenn Francis AMENDT, Gustaaf Maarten RUS, Pete VAN'T HOFF, Peng Xue WEN, Liu Xue WEN, Wu GANG, Jiang Jia ZHI